115 related articles for article (PubMed ID: 15501953)
1. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential.
Assikis VJ; Do KA; Wen S; Wang X; Cho-Vega JH; Brisbay S; Lopez R; Logothetis CJ; Troncoso P; Papandreou CN; McDonnell TJ
Clin Cancer Res; 2004 Oct; 10(20):6770-8. PubMed ID: 15501953
[TBL] [Abstract][Full Text] [Related]
2. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
Prensner JR; Zhao S; Erho N; Schipper M; Iyer MK; Dhanasekaran SM; Magi-Galluzzi C; Mehra R; Sahu A; Siddiqui J; Davicioni E; Den RB; Dicker AP; Karnes RJ; Wei JT; Klein EA; Jenkins RB; Chinnaiyan AM; Feng FY
Lancet Oncol; 2014 Dec; 15(13):1469-1480. PubMed ID: 25456366
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
[TBL] [Abstract][Full Text] [Related]
4. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.
Tzelepi V; Efstathiou E; Wen S; Troncoso P; Karlou M; Pettaway CA; Pisters LL; Hoang A; Logothetis CJ; Pagliaro LC
J Clin Oncol; 2011 Jun; 29(18):2574-81. PubMed ID: 21606419
[TBL] [Abstract][Full Text] [Related]
5. MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor.
Genitsch V; Zlobec I; Thalmann GN; Fleischmann A
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):242-7. PubMed ID: 27165976
[TBL] [Abstract][Full Text] [Related]
6. Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential.
Miller ET; You S; Cadaneanu RM; Kim M; Yoon J; Liu ST; Li X; Kwan L; Hodge J; Quist MJ; Grasso CS; Lewis MS; Knudsen BS; Freeman MR; Garraway IP
BMC Cancer; 2020 May; 20(1):398. PubMed ID: 32380981
[TBL] [Abstract][Full Text] [Related]
7. Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.
Becker F; Joerg V; Hupe MC; Roth D; Krupar R; Lubczyk V; Kuefer R; Sailer V; Duensing S; Kirfel J; Merseburger AS; Brägelmann J; Perner S; Offermann A
Int J Cancer; 2020 Jan; 146(2):577-588. PubMed ID: 31271443
[TBL] [Abstract][Full Text] [Related]
8. Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence.
Lorenzo GD; Bianco R; Tortora G; Ciardiello F
Clin Prostate Cancer; 2003 Jun; 2(1):50-7. PubMed ID: 15046685
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
[TBL] [Abstract][Full Text] [Related]
10. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
11. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
12. Personalized prediction of tumor response and cancer progression on prostate needle biopsy.
Donovan MJ; Khan FM; Fernandez G; Mesa-Tejada R; Sapir M; Zubek VB; Powell D; Fogarasi S; Vengrenyuk Y; Teverovskiy M; Segal MR; Karnes RJ; Gaffey TA; Busch C; Haggman M; Hlavcak P; Freedland SJ; Vollmer RT; Albertsen P; Costa J; Cordon-Cardo C
J Urol; 2009 Jul; 182(1):125-32. PubMed ID: 19450827
[TBL] [Abstract][Full Text] [Related]
13. TRIM24 as an independent prognostic biomarker for prostate cancer.
Offermann A; Roth D; Hupe MC; Hohensteiner S; Becker F; Joerg V; Carlsson J; Kuempers C; Ribbat-Idel J; Tharun L; Sailer V; Kirfel J; Svensson M; Andren O; Lubczyk V; Kuefer R; Merseburger AS; Perner S
Urol Oncol; 2019 Sep; 37(9):576.e1-576.e10. PubMed ID: 31178279
[TBL] [Abstract][Full Text] [Related]
14. Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures.
Grubb RL; Deng J; Pinto PA; Mohler JL; Chinnaiyan A; Rubin M; Linehan WM; Liotta LA; Petricoin EF; Wulfkuhle JD
J Proteome Res; 2009 Jun; 8(6):3044-54. PubMed ID: 19275204
[TBL] [Abstract][Full Text] [Related]
15. Neural protein gamma-synuclein interacting with androgen receptor promotes human prostate cancer progression.
Chen J; Jiao L; Xu C; Yu Y; Zhang Z; Chang Z; Deng Z; Sun Y
BMC Cancer; 2012 Dec; 12():593. PubMed ID: 23231703
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors.
Genitsch V; Zlobec I; Seiler R; Thalmann GN; Fleischmann A
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788048
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
18. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
19. Molecular markers for predicting prostate cancer stage and survival.
Dunsmuir WD; Gillett CE; Meyer LC; Young MP; Corbishley C; Eeles RA; Kirby RS
BJU Int; 2000 Nov; 86(7):869-78. PubMed ID: 11069416
[TBL] [Abstract][Full Text] [Related]
20. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
